CVRx reported preliminary first‑quarter 2026 revenue of $14.7 million to $14.8 million, a 20% year‑over‑year increase from $12.3 million in Q1 2025. The range exceeds the consensus estimate of $14.06 million, giving the company a revenue beat of roughly $0.64 million or 4.5% above expectations, driven by robust demand for its Barostim device and the expansion of its commercial footprint into five new U.S. territories.
Gross margin for the quarter rose to 87% from 84% in the same period last year, while operating expenses climbed to $25 million from $23.7 million. The margin expansion reflects pricing power and a favorable product mix, whereas the expense increase is largely attributable to sales‑force expansion and the activation of the first site in the BENEFIT‑HF trial, a strategic investment aimed at broadening the device’s indication.
The company added five new U.S. territories, bringing its total to 56, and increased active implanting centers to 257. Cash and cash equivalents stood at $72.3 million as of March 31 2026, providing a solid liquidity base to support ongoing commercial and clinical initiatives.
The transition to Category I CPT code 64654 improved 30‑day prior‑authorization approval rates for Medicare Advantage to 50% in January‑February 2026, up from 44% in 2025, easing a key reimbursement barrier. In addition, the first site in the BENEFIT‑HF trial was activated on March 31, marking a critical milestone for expanding the patient population eligible for Barostim.
Investors reacted cautiously, citing ongoing cash burn and valuation concerns despite the earnings beat. The market’s muted response reflects a focus on the company’s long‑term growth trajectory rather than short‑term price movements.
Management reaffirmed its full‑year 2026 revenue guidance of $63.0 million to $67.0 million, indicating confidence that the company is on track to meet or exceed its annual targets. The guidance, combined with the strong quarterly performance, signals a positive outlook for the remainder of the year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.